Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...
The collaboration operates within a fully transparent 𝐝𝐞𝐬𝐢𝐠𝐧–𝐦𝐚𝐤𝐞–𝐭𝐞𝐬𝐭–𝐚𝐧𝐚𝐥𝐲𝐳𝐞 (𝐃𝐌𝐓𝐀) framework that integrates AI-driven molecular design, rapid compound synthesis, and ...
Variational AI today announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results